Outcomes following iodine-125 prostate brachytherapy with or without neoadjuvant androgen deprivation

Abstract Purpose To report the biochemical failure-free survival (BFFS), cause-specific survival (CSS), and overall survival (OS) outcomes of patients treated with iodine-125 (I-125) brachytherapy for clinically localized prostate cancer. Methods and materials Between 2003 and 2009, I-125 permanent...

Full description

Saved in:
Bibliographic Details
Published in:Radiotherapy and oncology 2013-11, Vol.109 (2), p.241-245
Main Authors: Ohashi, Toshio, Yorozu, Atsunori, Saito, Shiro, Momma, Tetsuo, Toya, Kazuhito, Nishiyama, Toru, Yamashita, Shoji, Shiraishi, Yutaka, Shigematsu, Naoyuki
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Brachytherapy
Brachytherapy - adverse effects
Brachytherapy - methods
Hematology, Oncology and Palliative Medicine
Humans
Iodine Radioisotopes - therapeutic use
Male
Middle Aged
Neoadjuvant Therapy
Proportional Hazards Models
Prostate cancer
Prostatic Neoplasms - mortality
Prostatic Neoplasms - radiotherapy
Radiotherapy Dosage
Seed implant
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Purpose To report the biochemical failure-free survival (BFFS), cause-specific survival (CSS), and overall survival (OS) outcomes of patients treated with iodine-125 (I-125) brachytherapy for clinically localized prostate cancer. Methods and materials Between 2003 and 2009, I-125 permanent prostate brachytherapy without supplemental external-beam radiotherapy was performed for 663 patients with low-risk and low-tier intermediate-risk (defined as organ-confined disease, PSA
ISSN:0167-8140
1879-0887
DOI:10.1016/j.radonc.2013.09.022